Allarity Secures U.S. Patent for Stenoparib Companion Diagnostic Until 2042
Event summary
- Allarity Therapeutics received a U.S. patent for its stenoparib DRP® companion diagnostic, valid until April 2042.
- The patent covers methods for predicting clinical benefit from stenoparib based on gene-expression profiles.
- Stenoparib is an orally available dual PARP and WNT pathway inhibitor in Phase 2 trials for ovarian cancer.
- Allarity has also secured patent protection for the DRP® in Europe and Australia until 2039.
The big picture
The U.S. patent grant strengthens Allarity's long-term intellectual property foundation for stenoparib, a dual PARP and WNT pathway inhibitor with potential applications across multiple cancer types. This move aligns with broader industry trends toward precision medicine and companion diagnostics, which aim to enhance patient selection and therapeutic outcomes. The patent protection until 2042 provides Allarity with a significant competitive advantage in the development of targeted cancer therapies.
What we're watching
- Regulatory Pathway
- Whether the FDA will accept the DRP® companion diagnostic strategy for regulatory approval.
- Clinical Validation
- The pace at which ongoing Phase 2 trials confirm stenoparib's efficacy in ovarian cancer and small cell lung cancer.
- Commercial Strategy
- How Allarity will leverage the patent exclusivity to position stenoparib in the competitive oncology market.
Related topics